We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-18.21%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.2B
AUM Growth
-$2.97B
Cap. Flow
+$24.4M
Cap. Flow %
0.2%
Top 10 Hldgs %
86.1%
Holding
101
New
4
Increased
12
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$219M
2
AMRN
Amarin Corp
AMRN
+$155M
3
KOD icon
Kodiak Sciences
KOD
+$81M
4
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$22.3M
5
KRYS icon
Krystal Biotech
KRYS
+$14M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$143M
2
SAGE
Sage Therapeutics
SAGE
+$80.2M
3
NVTA
Invitae Corporation
NVTA
+$58.3M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$45.3M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
76
DELISTED
Adamas Pharmaceuticals
ADMS
$1.47M 0.01%
172,630
– –
GLMD icon
77
Galmed Pharmaceuticals
GLMD
$4.48M
$1.47M 0.01%
150
-75
-33% -$1.05M
LJPC
78
DELISTED
La Jolla Pharmaceutical Company
LJPC
$1.46M 0.01%
154,675
– –
ARAV
79
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.42M 0.01%
404,384
-1
-0% -$6
RCUS icon
80
Arcus Biosciences
RCUS
$3.86B
$1.31M 0.01%
121,534
– –
MTEM
81
DELISTED
Molecular Templates, Inc.
MTEM
$1.03M 0.01%
16,949
– –
TRIL
82
DELISTED
Trillium Therapeutics Inc.
TRIL
$864K 0.01%
505,262
– –
DVAX
83
DELISTED
Dynavax Technologies
DVAX
$686K 0.01%
75,000
– –
INFI
84
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$685K 0.01%
580,400
– –
TARA icon
85
Protara Therapeutics
TARA
$228M
$678K 0.01%
7,465
– –
AQST icon
86
Aquestive Therapeutics
AQST
$585M
$627K 0.01%
99,600
– –
AFMD
87
DELISTED
Affimed
AFMD
$622K 0.01%
20,000
– –
CNST
88
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$535K ﹤0.01%
133,333
– –
FLGT icon
89
Fulgent Genetics
FLGT
$548M
$396K ﹤0.01%
125,000
– –
VIRX
90
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$231K ﹤0.01%
15,905
– –
AIXC
91
AIxCrypto Holdings Inc
AIXC
$22.7M
$168K ﹤0.01%
22
– –
ARWR icon
92
Arrowhead Research
ARWR
$12.3B
– –
-307,496
Closed -$5.89M
OVID icon
93
Ovid Therapeutics
OVID
$547M
– –
-222,139
Closed -$1.26M
SAGE
94
DELISTED
Sage Therapeutics
SAGE
– –
-567,497
Closed -$80.2M
PHXM
95
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
– –
-108,597
Closed -$9.31M
MNTA
96
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-308,500
Closed -$8.11M
ECYT
97
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-2,548,069
Closed -$45.3M
1 2 3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2018 Portfolio in Review

As of Q4 2018, Julian Baker held 101 positions worth $12.2B, down 20% from $15.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q4 2018 filing shows 4 new, 12 increased, 21 reduced and 10 closed positions. Its largest new stake was Kodiak Sciences: 9,145,115 shares worth $64.9M. The largest sale was Genomic Health, Inc., an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q4 2018 buy was Kodiak Sciences: 9,145,115 shares worth $64.9M.
  • Julian Baker added most to Acadia Pharmaceuticals in Q4 2018, an estimated $219M increase.
  • Julian Baker's biggest Q4 2018 reduction was Genomic Health, Inc., cutting an estimated $143M.
  • Julian Baker fully exited Sage Therapeutics in Q4 2018, selling an estimated $80.2M.
  • Julian Baker's ten largest holdings make up 86% of its $12.2B portfolio in Q4 2018.
  • Julian Baker opened 4 new positions and closed 10 in Q4 2018.
  • Julian Baker's portfolio value fell 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.